Pfizer's Monthly Obesity Drug Shows Steady Weight Loss But Trails Zepbound
Pfizer's berobenatide produced up to 12.1% weight loss over 28 weeks, with monthly dosing maintaining momentum — but still lags behind Eli Lilly's Zepbound.
Summary
Pfizer's obesity drug berobenatide, dosed monthly after an initial weekly phase, continued producing weight loss without plateauing at 28 weeks in a mid-stage clinical trial. Patients lost up to 12.1% of their body weight by that point. The key finding is that switching from weekly to monthly injections didn't slow progress — an important convenience advantage. However, the weight loss rate still falls short of what Eli Lilly's Zepbound achieved at a comparable stage. Berobenatide was originally developed by biotech Metsera and acquired by Pfizer. While monthly dosing could appeal to patients who struggle with weekly injections, whether this drug can compete in an increasingly crowded obesity treatment market remains an open question pending longer and larger trials.
Detailed Summary
The obesity drug landscape is evolving rapidly, and Pfizer is hoping its newly acquired compound berobenatide can carve out a niche — primarily through the convenience of monthly dosing. New data from the VESPER-3 mid-stage trial, presented at the American Diabetes Association's annual meeting, offer the most detailed look yet at how this drug performs when patients transition from weekly to monthly injections.
In the study, participants with obesity received weekly doses of berobenatide for 12 weeks before switching to higher monthly doses through week 28. By the end of the 28-week period, patients who stayed on treatment lost up to 12.1% of their body weight. Crucially, the rate of weight loss did not plateau after switching dosing schedules — a meaningful signal that monthly dosing maintains therapeutic momentum.
This matters because adherence is a well-documented challenge in chronic disease management. A once-monthly injectable could reduce treatment burden and potentially improve long-term compliance compared to weekly options like semaglutide or tirzepatide. For patients who find weekly injections inconvenient, a monthly alternative may represent a meaningful quality-of-life improvement.
However, the competitive picture is complicated. At the same 28-week time point, berobenatide's weight loss results were notably lower than those seen in the pivotal trial for Eli Lilly's Zepbound (tirzepatide), which has demonstrated up to 20%+ body weight reduction in longer trials. Efficacy remains the primary metric patients and clinicians weigh when choosing obesity therapies.
This was a mid-stage (Phase 2) trial, meaning the data are preliminary. The article is behind a paywall, limiting full access to detailed methodology, adverse event profiles, and patient demographics. Pfizer will need larger, longer Phase 3 trials to determine whether monthly convenience can offset a potential efficacy gap against market leaders.
Key Findings
- Berobenatide produced up to 12.1% body weight loss at 28 weeks in patients who stayed on treatment.
- Transitioning from weekly to monthly dosing did not slow weight loss or trigger an early plateau.
- Monthly dosing convenience could improve long-term adherence compared to weekly injectables.
- Weight loss rate at 28 weeks remains lower than Eli Lilly's Zepbound at a comparable trial stage.
- Data are from a mid-stage trial; larger Phase 3 studies are needed to confirm competitive viability.
Methodology
This is a news report from STAT News summarizing mid-stage (Phase 2) clinical trial data presented at the American Diabetes Association 2026 annual meeting. The full article is paywalled, limiting access to complete methodology. Evidence is based on conference-presented data, not yet peer-reviewed publication.
Study Limitations
The article is paywalled, restricting access to full trial methodology, adverse event data, and patient demographics. This is Phase 2 data presented at a conference and has not been peer-reviewed or published in full. Comparisons to Zepbound are cross-trial and not head-to-head, limiting direct conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.